Declining Incidence of Hepatitis C Virus Infection among People Who Inject Drugs in a Canadian Setting, 1996-2012
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: People who inject drugs (PWID) are at high risk of hepatitis C virus (HCV) infection. Trends in HCV incidence and associated risk factors among PWID recruited between 1996 and 2012 in Vancouver, Canada were evaluated. METHODS: Data were derived from a long-term cohort of PWID in Vancouver. Trends in HCV incidence were evaluated. Factors associated with time to HCV infection were assessed using Cox proportional hazards regression. RESULTS: Among 2,589, 82% (n = 2,121) were HCV antibody-positive at enrollment. Among 364 HCV antibody-negative participants with recent (last 30 days) injecting at enrollment, 126 HCV seroconversions were observed [Overall HCV incidence density: 8.6 cases/100 person-years (py); 95% confidence interval (95% CI): 7.2, 10.1; HCV incidence density among those with injecting during follow-up: 11.5 cases/100 py; 95% CI 9.7, 13.6]. The overall HCV incidence density declined significantly from 25.0/100 py (95% CI: 20.2, 30.3) in 1996-99, as compared to 6.0/100 py (95% CI: 4.1, 8.5) in 2000-2005, and 3.1/100 py (95% CI: 2.0, 4.8) in 2006-2012. Among those with injecting during follow-up, the overall HCV incidence density declined significantly from 27.9/100 py (95% CI: 22.6, 33.6) in 1996-99, as compared to 7.5/100 py (95% CI: 5.1, 10.6) in 2000-2005, and 4.9/100 py (95% CI: 3.1, 7.4) in 2006-2012. Unstable housing, HIV infection, and injecting of cocaine, heroin and methamphetamine were independently associated with HCV seroconversion. CONCLUSIONS: HCV incidence has dramatically declined among PWID in this setting. However, improved public health strategies to prevent and treat HCV are urgently required to reduce HCV-associated morbidity and mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




![Figure 5 Incidence density of HCV infection (per 100 person-years) among PWID in the VIDUS cohort by calendar year of enrolment and calendar year of observation. Each shaded area is a proportion relative to the largest incidence rate with 25.0 being 1 (full shading). The numeric values of the rates are used as the labels [95% CI]. Cells with N/A are blank.](https://figures.cochat.ai/paper-figures/4c3dfd0438e8465791fb9043ee1eccbc/declining-incidence-of-hepatitis-c-virus-infection-among-people-who-inject-drugs-figure-5.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite dramatic reductions of HCV infection rates reported between 1996 and 2012 (Grebely et al. 2014), unstable housing continues to be an independent predictor associated with HCV infection (Grebely et al. 2014).”
From Clinical and functional characteristics of young adults living in single room occupancy housing: preliminary findings from a 10-year longitudinal study (2018) · cites this paper as Grebely et al. 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nelson, P. K., Mathers, B. M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., & Degenhardt, L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61097-0 · Cited by 1,267 · cited 1×
“Globally, it is estimated that 10 million PWID are HCV-infected worldwide, corresponding to a mid-point prevalence of 67% [1].”
BackgroundSharing of drug preparation equipment as a risk factor for hepatitis C
(2001) · American Journal of Public Health · doi:10.2105/ajph.91.1.42 · Cited by 500
Martin, N. K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S. J., Lima, V. D., Foster, G. R., Dillon, J. F., Goldberg, D. J., Dore, G. J., et al. (2013) · Hepatology · doi:10.1002/hep.26431 · Cited by 488
Self-citationPage, K., Hahn, J. A., Evans, J., Shiboski, S., Lum, P., Delwart, E., Tobler, L., Andrews, W., Avanesyan, L., Cooper, S., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/605947 · Cited by 285
Miller, C. L., Johnston, C., Spittal, P. M., Li, K., LaLiberté, N., Montaner, J. S. G., & Schechter, M. T. (2002) · Hepatology · doi:10.1053/jhep.2002.35065 · Cited by 259
Self-citationProspective Evaluation of Community‐Acquired Acute‐Phase Hepatitis C Virus Infection
Cox, A. L., Netski, D. M., Mosbruger, T., Sherman, S. G., Strathdee, S., Ompad, D., Vlahov, D., Chien, D., Shyamala, V., Ray, S. C., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/428578 · Cited by 231
Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia
Maher, L., Jalaludin, B., Chant, K. G., Jayasuriya, R., Sladden, T., Kaldor, J. M., & Sargent, P. L. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01543.x · Cited by 227 · cited 1×
“Consistent with previous studies, unstable housing [17], injecting cocaine use [4,5,9,11,14,16,17] and injecting heroin use [9,11,17] were associated with HCV infection in this study.”
ResultPatrick, D. M., TYNDALL, M. W., Cornelisse, P., Li, K. K., Sherlock, C. H., Rekart, M. L., Strathdee, S. A., Currie, S. L., Schechter, M. T., & O’Shaughnessy, M. V. (2001) · Europe PMC (PubMed Central) · Cited by 203
Bruneau, J., Roy, É., Arruda, N., Zang, G., & Jutras‐Aswad, D. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.03803.x · Cited by 171
Hepatitis C Virus Infection Among Injection Drug Users: Survival Analysis of Time to Seroconversion
Hagan, H., Thiede, H., & Des Jarlais, D. C. (2004) · Epidemiology · doi:10.1097/01.ede.0000135170.54913.9d · Cited by 170
Cited by
Platt, L., Minozzi, S., Reed, J., Vickerman, P., Hagan, H., French, C., Jordan, A., Degenhardt, L., Hope, V., Hutchinson, S., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012021.pub2 · Cited by 305
Degenhardt, L., Charlson, F., Stanaway, J., Larney, S., Alexander, L. T., Hickman, M., Cowie, B., Hall, W. D., Strang, J., Whiteford, H., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30325-5 · Cited by 305
Mixed HCV infection and reinfection in people who inject drugs—impact on therapy
Cunningham, E. B., Applegate, T. L., Lloyd, A. R., Dore, G. J., & Grebely, J. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.36 · Cited by 105
Self-citationArtenie, A. A., Stone, J., Fraser, H., Stewart, D. E., Arum, C., Lim, A. G., McNaughton, A. L., Trickey, A., Ward, Z., Abramovitz, D. A., et al. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00018-3 · Cited by 114
Self-citationBartlett, S. R., Yu, A., Chapinal, N., Rossi, C., Butt, Z. A., Wong, S., Darvishian, M., Gilbert, M., Wong, J., Binka, M., et al. (2019) · Liver International · doi:10.1111/liv.14227 · Cited by 94
Self-citation
Metadata
- Authors
- Grebely, J., Lima, V. D., Marshall, B. D. L., Milloy, M.-J., DeBeck, K., Montaner, J., Simo, A., Krajden, M., Dore, G. J., Kerr, T., & Wood, E.
- Affiliations
- UNSW Sydney (AU)
- University of British Columbia (CA)
- Brown University (US)
- Simon Fraser University (CA)
- BC Centre for Disease Control (CA)
- Corresponding author
- Grebely, Jason
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-06-04
- Volume
- 9
- Issue
- 6
- Pages
- e97726
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4045728
- OpenAlex
- W2038073312
- Cited by
- 48
- References
- 37
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2021: 4 · 2020: 6 · 2019: 3 · 2018: 6 · 2017: 6 · 2016: 8 · 2015: 9 · 2014: 2
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Summit (Simon Fraser University) (submittedVersion, cc-by)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by)
- Funders
- Bristol-Myers Squibb
- World Health Organization
- Gilead Sciences
- UNICEF
- U.S. President’s Emergency Plan for AIDS Relief
- ViiV Healthcare
- Providence Health Care
- Australian Government
- Michael Smith Health Research BC
- Canada Research Chairs (Tier1)
- Simon Fraser University
- Ministry of Health, British Columbia (1DP1DA026182, R01DA011591)
- University of British Columbia
- International AIDS Society
- National Institutes of Health
- Canadian Institutes of Health Research (R01DA011591, RAA- 79918, HES- 115697, 129971_1, 125948_1, HHP- 67262)
- National Health and Medical Research Council
- National Institute on Drug Abuse (DP1DA026182, R03DA033851, R01DA011591)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatitis C virus research
- Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- hepatitis C virus, people who inject drugs, HCV seroconversion, intravenous drug use, cocaine use, heroin use, methamphetamine use, HIV coinfection, unstable housing, risk factors, Vancouver, harm reduction, needle exchange programs, HCV screening, HCV seroprevalence
- MeSH terms
- Adult, Canada, Female, Hepatitis C, Humans, Male, Surveys and Questionnaires, Risk Factors, Substance Abuse, Intravenous, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Declining Incidence of Hepatitis C Virus Infection among People Who Inject Drugs in a Canadian Setting, 1996-2012. https://app.cochat.ai/papers/10.1371/journal.pone.0097726
- The paper
- Grebely, J., Lima, V. D., Marshall, B. D. L., Milloy, M.-J., DeBeck, K., Montaner, J., Simo, A., Krajden, M., Dore, G. J., Kerr, T., & Wood, E. (2014). Declining Incidence of Hepatitis C Virus Infection among People Who Inject Drugs in a Canadian Setting, 1996-2012. PLoS ONE. https://doi.org/10.1371/journal.pone.0097726
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.